Automated prediction of drug reactogenicity at the site of injection, by combining natural human skin & computational inference of biological pathways.

This approach empowers patients to self-administer treatment at home. However, the majority of biologics are associated with adverse neuro-inflammatory effects at the site of injection, mediated by secreted cytokines and chemokines. Anticipating these effects prior to clinical trials is critical, especially in a context that closely replicates human biological features.

Objective: Understand biological processes activated by Cetrotide^® injection, a medication known for causing edema, redness, itch, and pain at the injection site.
Method: Utilize the ImmunoSafe ISR Platform^® integrating HypoSkin®, secretome profiling, and computational analysis across seven distinct donors.
Key Findings:Identified a specific secretomic signature post-Cetrotide^® injection, highlighting immune response and neuroinflammatory pathways.
Demonstrated the effectiveness of combining HypoSkin^® with computational analysis for preclinical assessment of injection site reactions.

By leveraging HypoSkin^® within the ImmunoSafe ISR Platform^®, we offer an advanced, human-relevant model to predict and mitigate potential adverse effects, paving the way for safer and more patient-friendly therapeutics.

Poster presented at EUROTOX 2023 highlighting the Power of AUDACY associated with multiplex cytokine analysis

Rapid and Precise Data Analysis: AUDACY swiftly processes large datasets to identify differentially expressed proteins, reducing the potential for human error and significantly accelerating research timelines.
In-depth Biological Insights: By leveraging public literature and databases, AUDACY correlates identified proteins with biological pathways and protein-protein interactions, offering a comprehensive view of potential toxicological effects.